ProShare Advisors
NWBO

ProShare Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

ProShare Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-14,116
Closed -$71K – 2349
2014
Q3 		$71K Sell
14,116
-3,201
-18% -$19.7K ﹤0.01% 2223
2014
Q2 		$116K Buy
+17,317
New +$110K ﹤0.01% 2326

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

ProShare Advisors's NWBO Position: Q4 2014 in Review

ProShare Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2014, closing a stake of 14,116 shares — an estimated $71K sold.

ProShare Advisors first reported a position in NWBO in Q2 2014 and held it in 2 quarters. The position peaked at $116K in Q2 2014. 70 funds tracked by Wall St. Rank hold NWBO as of Q4 2014.

  • ProShare Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2014 after selling out during the quarter.
  • ProShare Advisors sold 14,116 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2014, an estimated $71K.
  • ProShare Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 2 quarters.
  • ProShare Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $116K in Q2 2014.
  • 70 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2014.

Based on ProShare Advisors's 13F filing for Q4 2014, filed 30 Jan 2015.